Communiqués ExpreS2ion Biotech Holding AB

Actions

EXPRS2

SE0008348262

Temps Différé Nasdaq Stockholm Autres places de cotation 17:07:34 17/07/2024			Varia. 5j.	Varia. 1 janv.
1,036 ^SEK	-4,25 %		-5,30 %	-50,90 %

16/05	ExpreS2ion Biotech Holding AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
16/04	ExpreS2ion annonce l'achèvement de l'étude de sécurité GLP pour le candidat vaccin ES2B-C001 (HER2-VLP) contre le cancer du sein	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

ExpreS2ion resolves on a directed issue of units to guarantors in connection with the completed rights issue	05/07	AQ
ExpreS2ion announces U.S. patent issue notification for glyco-engineered immunization antigens	03/07	AQ
ExpreS2ion announces final outcome of its rights issue	01/07	AQ
Rights issue subscription period ending 27 June 2024; subscription possible via form	26/06	AQ
ExpreS2ion announces poster presentation on the use of glycoengineered Drosophila S2 cells for production of highly immunogenic antigens at the ESACT meeting	24/06	AQ
Publication of clinical Phase Ib trial data for the adjuvanted RH5.1 blood-stage malaria vaccine	21/06	AQ
ExpreS2ion hosts informative webinar on 2024 Rights Issue and Highlights Key Updates on HER2+ Breast Cancer Vaccine	18/06	AQ
BioStock: Rights issue takes Expres2ion breast cancer vaccine to phase I	14/06	AQ
ExpreS2ion CEO to BioStock: "Compelling preclinical package gives us confidence"	12/06	AQ
The subscription period in ExpreS2ion's rights issue begins today	12/06	AQ
ExpreS2ion to present in upcoming investor and scientific events	10/06	AQ
ExpreS2ion publishes prospectus in connection with its rights issue of units	05/06	AQ
Bulletin from the Annual General Meeting of ExpreS2ion Biotech Holding AB held on 5 June 2024	05/06	AQ
ExpreS2ion Biotech : Interim report for January – March 2024 (Q1)	16/05	PU
ExpreS2ion announces financial results for the first quarter of 2024	16/05	AQ
ExpreS2ion to present in spring investor events	15/05	AQ
ExpreS2ion Biotech : Annual report 2023 including Auditor’s report	08/05	PU
ExpreS2ion annual report for 2023 published	08/05	AQ
Notice to attend the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)	03/05	AQ
ExpreS2ion announces a rights issue of units of approximately SEK 60 million	02/05	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués ExpreS2ion Biotech Holding AB

Actions

EXPRS2

SE0008348262

Communiqués

Filtres